Berkshire Hathaway more than doubles Constellation Brands stake

Sam Boughedda

Fri, May 16, 2025, 7:57 AM 1 min read

Investing.com -- Berkshire Hathaway has importantly accrued its concern successful Constellation Brands (NYSE:STZ), much than doubling its involvement successful the alcoholic beverage institution during the archetypal 4th of 2025.

According to a regulatory filing released Thursday, Warren Buffett’s conglomerate raised its holdings successful Constellation to astir 12 cardinal shares, up from 5.6 cardinal astatine the extremity of 2024.

The position, present valued astatine $2.2 billion, gives Berkshire a 6.6% involvement successful the company.

Shares of Constellation Brands are up astir 1.5% truthful acold connected Friday.

Meanwhile, Berkshire reduced its vulnerability to financials, exiting its involvement successful Citigroup (NYSE:C) and nary longer reporting a presumption successful the genitor of Brazilian fintech Nubank.

The steadfast besides chopped backmost its holdings successful Bank of America, present astatine 632 cardinal shares, and trimmed its presumption successful Capital One (NYSE:COF), which is successful the process of acquiring Discover Financial.

Berkshire remained a nett seller of equities for the 10th consecutive quarter, buying $3.18 cardinal and selling $4.68 cardinal successful stocks betwixt January and March. It ended the 4th with $347.7 cardinal successful currency and equivalents.

The company’s largest holding remains Apple (NASDAQ:AAPL), with a 300 cardinal stock involvement worthy $66.6 billion.

While Buffett’s sanction is inactive connected the filing, the banal prime whitethorn not beryllium his. Earlier this month, helium announced plans to measurement down arsenic Berkshire CEO astatine the extremity of the year, handing implicit the reins to Vice-Chairman Greg Abel.

Related articles

Berkshire Hathaway much than doubles Constellation Brands stake

HSBC lifts Carnival Corp. standing arsenic it is present ‘in calmer waters’

UBS upgrades Caterpillar arsenic commercialized risks ease, but macro uncertainty remains